1. Home
  2. MYO vs XBIT Comparison

MYO vs XBIT Comparison

Compare MYO & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myomo Inc.

MYO

Myomo Inc.

HOLD

Current Price

$1.23

Market Cap

63.8M

Sector

Health Care

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$1.93

Market Cap

69.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYO
XBIT
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.8M
69.8M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
MYO
XBIT
Price
$1.23
$1.93
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
★ $4.64
N/A
AVG Volume (30 Days)
★ 247.3K
53.2K
Earning Date
11-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $1,000,000,000.00
N/A
Revenue This Year
$11.43
N/A
Revenue Next Year
$12.29
$30.47
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 40814.79
N/A
52 Week Low
$0.61
$1.91
52 Week High
$1.89
$3.44

Technical Indicators

Market Signals
Indicator
MYO
XBIT
Relative Strength Index (RSI) 37.29 25.20
Support Level $1.18 N/A
Resistance Level $1.75 $2.42
Average True Range (ATR) 0.11 0.09
MACD -0.02 -0.03
Stochastic Oscillator 6.67 10.64

Price Performance

Historical Comparison
MYO
XBIT

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: